Advertisement

Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response

  • Gokhan DemirEmail author
  • Abdullah Ozkaya
  • Elmas Yuksel
  • Gurkan Erdogan
  • Ugur Tunc
  • Mevlut Celal Ocal
  • Yasin Sakır Goker
Original Research Article
  • 33 Downloads

Abstract

Background and Objective

Patients with diabetic macular edema may not have optimal outcomes even with monthly ranibizumab intravitreal injections. A corticosteroid implant might be considered in such patients. The objective of this study was to compare the outcomes of switching from ranibizumab to an intravitreal dexamethasone implant after three or six consecutive monthly injections of ranibizumab.

Methods

Patients with treatment-naïve diabetic macular edema who showed a poor anatomical response to three or six consecutive intravitreal ranibizumab injections and received an intravitreal dexamethasone implant were enrolled in this retrospective study. Patients were divided into two groups as early- and late-switch groups. The early-switch group consisted of the patients who initially received three consecutive monthly ranibizumab injections and the late-switch group consisted of the patients who initially received six consecutive monthly ranibizumab injections and switched to a dexamethasone implant because of a poor anatomical response. Best corrected visual acuity and central retinal thickness at the baseline and 3, 6, 9, and 12 months in the study population were recorded.

Results

Sixty-eight eyes of 68 patients were included. The early-switch group consisted of 34 eyes and the late-switch group consisted of 34 eyes. The mean change in best corrected visual acuity was similar between the two groups at 3, 9, and 12 months; however, it was significantly better in the early-switch group than the late-switch group at 6 months. The change in central retinal thickness was similar between the two groups at 3, 9, and 12 months; however, it was significantly better in the early-switch group than the late-switch group at 6 months.

Conclusions

Although both early switching and late switching are similar in terms of providing functional and morphological improvement, early switching appeared better for ensuring patient well-being in the early period and improving patient adherence.

Notes

Compliance with Ethical Standards

Funding

No funding was received for this conduct of this study or the preparation of this article.

Conflict of interest

Gokhan Demir, Abdullah Ozkaya, Elmas Yuksel, Gurkan Erdogan, Ugur Tunc, Mevlut Celal Ocal, and Yasin Sakır Goker have no conflicts of interest that are directly relevant to the content of this article.

Ethical approval

This study adhered to the tenets of the Declaration of Helsinki and received approval from the local ethics committee.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: changing trends in the management of diabetic macular edema at a single institution over the past decade. Retina. 2015;35:929–34.CrossRefGoogle Scholar
  2. 2.
    Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report No. 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:265–72.Google Scholar
  3. 3.
    Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–9.CrossRefGoogle Scholar
  4. 4.
    Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064.e35–1077.e35.Google Scholar
  5. 5.
    Ozkaya A, Alagoz C, Alagoz N, Gunes H, Yilmaz I, Perente I, et al. Dexamethasone implant in pseudophakic and nonglaucomatous subgroup of diabetic macular edema patients: a real life experience. Eur J Ophthalmol. 2016;26:351–5.CrossRefGoogle Scholar
  6. 6.
    Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.CrossRefGoogle Scholar
  7. 7.
    Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66–71.CrossRefGoogle Scholar
  8. 8.
    Bressler SB, Glassman AR, Almukhtar T, et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol. 2016;164:57–68.CrossRefGoogle Scholar
  9. 9.
    Yu SY, Nam DH, Lee DY. Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):39–47.CrossRefGoogle Scholar
  10. 10.
    Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci. 2015;56(11):6501–5.CrossRefGoogle Scholar
  11. 11.
    Massin P, Bandello F, Garweg J, Hansen L, Harding S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399–405.CrossRefGoogle Scholar
  12. 12.
    Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25.CrossRefGoogle Scholar
  13. 13.
    Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787–95.CrossRefGoogle Scholar
  14. 14.
    Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–81.CrossRefGoogle Scholar
  15. 15.
    Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.CrossRefGoogle Scholar
  16. 16.
    Fraser-Bell S, Lim LL, Campain A, et al. Bevacizumab or dexamethasone implants for DME: 2-year results (the BEVORDEX study). Ophthalmology. 2016;123(6):1399–401.CrossRefGoogle Scholar
  17. 17.
    Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of Protocol I data. Am J Ophthalmol. 2016;172:72–9.CrossRefGoogle Scholar
  18. 18.
    Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–49.CrossRefGoogle Scholar
  19. 19.
    Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Bio Pharm Bull. 2008;31:1541–6.CrossRefGoogle Scholar
  20. 20.
    Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res. 2005;30:949–57.CrossRefGoogle Scholar
  21. 21.
    Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141–6.CrossRefGoogle Scholar
  22. 22.
    Pacella F, Romano MR, Turchetti P, Carnovale A, Mollicone A, Mastromatteo A, et al. An eighteenmonth follow-up study on the effects of intravitreal dsexamethasone Implant in diabetic macular edema refractory to antiVEGF therapy. Int J Ophthalmol. 2016;9(10):1427–32.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Khan Z, Kuriakose RK, Khan M, Chin EK, Almeida DR. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):160–6.CrossRefGoogle Scholar
  24. 24.
    Totan Y, Güler E, Gürağaç FB. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res. 2016;41(1):107–13.CrossRefGoogle Scholar
  25. 25.
    Busch C, Zur D, Fraser-Bell S, Laíns I, Santos AR, Lupidi M, International Retina Group, et al. Shall we stay, or shall we switch? Continued antiVEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55(8):789–96.CrossRefGoogle Scholar
  26. 26.
    Bonfiglio V, Reibaldi M, Pizzo A, Russo A, Macchi I, Faro G, et al. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers. Acta Ophthalmol. 2019;97(4):e540–4.CrossRefGoogle Scholar
  27. 27.
    Nalçacı S, Akkın C, Afrashi F. Dexamethasone implant in patients with diabetic macular edema resistant to anti-VEGF therapy. Turk J Ophthalmol. 2019;49(2):73–7.CrossRefGoogle Scholar
  28. 28.
    Cakir A, Erden B, Bolukbasi S, Bayat AH, Ozturan SG, Elcioglu MN. Dexamethasone implant as an adjuvant therapy to ranibizumab loading dose in persistent diabetic macular edema. Int Ophthalmol. 2018.  https://doi.org/10.1007/s10792-018-1053-5.CrossRefPubMedGoogle Scholar
  29. 29.
    Demircan A, Alkin Z, Yesilkaya C, Demir G, Kemer B. Comparison of intravitreal aflibercept and ranibizumab following initial treatment with ranibizumab in persistent diabetic macular edema. J Ophthalmol. 2018;19(2018):4171628.  https://doi.org/10.1155/2018/4171628.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Beyoglu Eye Training and Research HospitalUniversity of Health SciencesIstanbulTurkey
  2. 2.Memorial Sisli HospitalIstanbulTurkey
  3. 3.Ankara Ulucanlar Eye Training and Research HospitalAnkaraTurkey

Personalised recommendations